Browse articles from EyeWorld.org on the topic of the cornea. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
There are several options for antiviral treatments for HSV, and in this article, two ophthalmologists spoke about the topical and oral options, when to get patients treated, how quickly the treatment works, and how this can impact patients in the future.
For years, ophthalmologists had limited prescription options for patients with ocular surface disease. In the last decade, the number of available options has grown with several receiving approval in 2023. Two experts shared their thoughts and experiences with these new options.
“As we continue to see progress in ocular surface therapeutics, we need to continue to evolve our vocabulary surrounding ocular surface disease. I challenge you to start differentiating your ‘dry eye’ patients as you see them in clinic,” said Cornea Editor Julie Schallhorn, MD. Read her introduction to the Cornea section for more details.
➤ Allogenic cell therapy receives FDA designations ➤ Robot delivers new treatment for wet AMD ➤ Health-related quality of life measure proposed for MIGS ➤ Company meets with FDA for pediatric myopia drug candidate ➤ ASCRS news and events
Who are the best patients? What are the outcomes like? What’s in store for the future? Three physicians answered these questions and more as they pertain to platelet-derived ocular surface therapies, giving insights on what they wish ophthalmologists knew about these products.
➤ FDA clears fully autonomous, portable AI device for diabetic retinopathy screening ➤ Positive preliminary data for Phase 1/2 trial evaluating gene therapy treatment for X-linked retinoschisis ➤ Dosing in Phase 1/2 trial for allogenic cell therapy for corneal edema ➤ Dosing complete in trial assessing corneal edema therapy ➤ Phase 4 results for mydriasis product reported ➤ Collaboration seeks to commercialize Alzheimer’s detection through retinal imaging ➤ ASCRS news and events
➤ First patient enrolled in Phase 3 trial evaluating phentolamine ophthalmic solution ➤ FDA clears IND amendment for Phase 3 retinitis pigmentosa gene therapy study ➤ Successful pre-submission meetings held for bioengineered corneal implants ➤ Study: AI chatbots pass ophthalmology board certification questions ➤ ASCRS news and events
➤ Phase 3 results for new corticosteroid ➤ Positive topline results from Phase 3 trials investigating presbyopia drop ➤ Phase 2 data presented for IOP-lowering intracameral implant ➤ First patient dosed in retinitis pigmentosa gene therapy ➤ Survey shows burden of pterygium ➤ ASCRS news and events
➤ One-year data from first-in-human drug eluting IOL ➤ Company begins two Phase 2 studies for glaucoma treatment ➤ First patient dosed in allogenic cell therapy trial ➤ Company outlines resubmission plan for reproxalap NDA ➤ Safety information for the upcoming solar eclipse ➤ Upcoming company presentations at Eyecelerator and the ASCRS Annual Meeting ➤ Complimentary access to video journal ➤ ASCRS news and events
Two physicians detailed Ocular Surface Stem Cell Transplantation with Systemic Immunosuppression for the treatment of severe ocular surface disease with limbal stem cell deficiency and obstacles to its adoption among corneal surgeons.